Findings in the Area of Cervical Cancer Reported from Suzhou Municipal Hospital (Effect of Epirubicin Combined With Docetaxel On Inflammatory Factors, Cytokines, Tumor Markers, Clinical Efficacy and Adverse Reactions In Patients With Cervical...).

A study conducted at Suzhou Municipal Hospital in Jiangsu, China, investigated the clinical efficacy of combining epirubicin and docetaxel in postoperative cervical cancer patients. The study randomly assigned 124 patients into two groups, with one group receiving intravenous epirubicin and the other receiving intravenous docetaxel in addition to epirubicin. After three courses of treatment, the experimental group showed lower levels of inflammatory factors and cytokines compared to the control group. Additionally, tumor markers were lower in the experimental group, and the disease control rate was higher. The study concluded that the combination of epirubicin and docetaxel is effective in treating postoperative cervical cancer. [Extracted from the article]